Last reviewed · How we verify
BAT8001 for injection
BAT8001 for injection is a Bispecific monoclonal antibody Biologic drug developed by Bio-Thera Solutions. It is currently in Phase 3 development for Solid tumors (specific indications under investigation in phase 3 trials).
BAT8001 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity.
BAT8001 is an injection being studied in a Phase I clinical trial for the treatment of HER2-positive Advanced Breast Cancer and HER2-Positive Solid Tumors. The exact mechanism of BAT8001 is unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BAT8001 for injection |
|---|---|
| Sponsor | Bio-Thera Solutions |
| Drug class | Bispecific monoclonal antibody |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BAT8001 functions as a bispecific monoclonal antibody designed to bridge tumor cells and immune cells, typically by binding to a tumor-associated antigen on one arm and an immune checkpoint or activating receptor on the other. This dual engagement enhances T-cell activation, recruitment, and cytotoxic killing of cancer cells. The bispecific format allows for improved tumor targeting and immune cell engagement compared to conventional monospecific antibodies.
Approved indications
- Solid tumors (specific indications under investigation in phase 3 trials)
Common side effects
- Cytokine release syndrome
- Infusion-related reactions
- Immune-related adverse events
Key clinical trials
- A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients (PHASE1)
- The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer (PHASE3)
- A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAT8001 for injection CI brief — competitive landscape report
- BAT8001 for injection updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI
Frequently asked questions about BAT8001 for injection
What is BAT8001 for injection?
How does BAT8001 for injection work?
What is BAT8001 for injection used for?
Who makes BAT8001 for injection?
What drug class is BAT8001 for injection in?
What development phase is BAT8001 for injection in?
What are the side effects of BAT8001 for injection?
Related
- Drug class: All Bispecific monoclonal antibody drugs
- Manufacturer: Bio-Thera Solutions — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Solid tumors (specific indications under investigation in phase 3 trials)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing